Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Coo
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 4516-4516
10.1200/jco.2004.22.90140.4516